Photocure ASA
OSE:PHO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Photocure ASA
Revenue
Photocure ASA
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Photocure ASA
OSE:PHO
|
Revenue
kr532.6m
|
CAGR 3-Years
11%
|
CAGR 5-Years
16%
|
CAGR 10-Years
15%
|
|
|
V
|
Vistin Pharma ASA
OSE:VISTN
|
Revenue
kr452.3m
|
CAGR 3-Years
16%
|
CAGR 5-Years
12%
|
CAGR 10-Years
8%
|
|
|
N
|
Navamedic ASA
OSE:NAVA
|
Revenue
kr565.4m
|
CAGR 3-Years
14%
|
CAGR 5-Years
22%
|
CAGR 10-Years
9%
|
|
|
S
|
SoftOx Solutions AS
OSE:SOFTX
|
Revenue
kr10.5m
|
CAGR 3-Years
19%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
|
O
|
Oncoinvent ASA
OSE:ONCIN
|
Revenue
kr5.4m
|
CAGR 3-Years
91%
|
CAGR 5-Years
90%
|
CAGR 10-Years
N/A
|
|
Photocure ASA
Glance View
Photocure ASA delivers transformative solutions to improve the lives of bladder cancer patients. The company is headquartered in Oslo, Oslo. The company went IPO on 2000-05-29. The company operates in the field of photodynamic diagnosis, cosmetics and treatment of acne, bladder cancer, colon cancer, as well as human papilloma virus (HPV) and precancerous lesions of the cervix. The Company’s activities comprise research, development and commercialization of pipeline projects within two segments: Cancer and Dermatology. Its brand portfolio includes: Hexvix and Cysview, for detection and management of bladder cancer; Visonac, for acne treatment; Cevira, used in HPV and precancerous lesions of the cervix treatment; and Lumacan, applied in colorectal cancer treatment. Furthermore, It owns a Photocure Technology platform, which develops photodynamic technology for diagnosis and therapy. The firm is a parent of a wholly owned entity, Photocure Inc.
See Also
What is Photocure ASA's Revenue?
Revenue
532.6m
NOK
Based on the financial report for Dec 31, 2025, Photocure ASA's Revenue amounts to 532.6m NOK.
What is Photocure ASA's Revenue growth rate?
Revenue CAGR 10Y
15%
Over the last year, the Revenue growth was 1%. The average annual Revenue growth rates for Photocure ASA have been 11% over the past three years , 16% over the past five years , and 15% over the past ten years .
